A phase 2 study of the combination of gemcitabine and cisplatin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines with/without taxanes
BACKGROUND AND OBJECTIVES: Many patients with relapsed metastatic breast cancer are pre-treated with taxanes and anthracyclines, which are usually given in the neoadjuvant/adjuvant setting or as first-line treatment for metastatic disease. The primary objective of this study was to determine the ove...
Main Authors: | Hanna Kohail, Samir Shehata, Omar Mansour, Youssri Gouda, Rabbab Gaafar, Thoraya Abdel Hamid, Saiid El Nowieam, Ahmed Al Khodary, Heba El Zawahry, Ahmed Abdel Wareth, Iman Abdel Halim, Fouad Abou Taleb, Emad Hamada, Mohsen Barsoum, Mohamed Abdullah, Mohamed Meshref |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2012-01-01
|
Series: | Hematology/Oncology and Stem Cell Therapy |
Online Access: | http://www.sciencedirect.com/science/article/pii/S165838761250004X |
Similar Items
-
ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers
by: Tarek M. A. Abdel-Fatah, et al.
Published: (2019-08-01) -
Gemcitabine and taxanes in metastatic breast cancer: a systematic review
by: Vinay Gudena, et al.
Published: (2008-10-01) -
A phase II study of gemcitabine combined with vinorelbine as first-line chemotherapy for metastatic breast cancer
by: Samir Shehata, et al.
Published: (2010-01-01) -
Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
by: Wanjing Chen, et al.
Published: (2021-02-01) -
Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer.
by: Pedro Veronese, et al.
Published: (2018-01-01)